Vestar Inc. deal

VSTR now has worldwide rights for AmBisome, excluding the U.S. and Canada, which Fujisawa retains. Michael Hart, VSTR's CFO, said Fujisawa has concentrated on the U.S. and Canada, and had not invested to advance the Asian development of AmBisome. Asian clinical trials have not begun. The drug is Phase I U.S. trials to treat systemic fungal infections. It already has received marketing approval in Europe for the same indication. ...